Protocol Ledger

NCT06901531 · Phase III · RECRUITING

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Interventional Phase III clinical trial protocol NCT06901531 sponsored by Astellas Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-22 Enrollment: 500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06901531
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06901531
Protocol FieldVerified Registry Value
NCT IdentifierNCT06901531
Consolidated Lead SponsorAstellas Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment500 participants (ESTIMATED)
Registered Start Date2025-05-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI